Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats

Endocrinology

Volumn 141, Issue 6, 2000, Pages 1936-1941

  Szayna, Margarzata ^a   Doyle, Máire E ^a   Betkey, Jennifer A ^a   Holloway, Harold W ^a   Spencer, Richard G S ^a   Greig, Nigel H ^a   Egan, Josephine M ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APPETITE; ARTICLE; CONTROLLED STUDY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN BLOOD LEVEL; INSULIN LIKE ACTIVITY; LIPID STORAGE; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SALIVARY GLAND; SEQUENCE HOMOLOGY; WEIGHT GAIN;

EID: 0034456212     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.141.6.7490     Document Type: Article

References (23)

1. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom: Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
2. Tissue-specific expression of unique mRNAs that encode pro-glucagon-derived peptides or exendin 4 in the lizard
3. Once daffy injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations
4. Exendin-4 is a potent agonist and truncated exendin-(9-39)-amide an antagonist at the GLP-1-(7-36)-amide receptor of insulin-secreting β-cells
5. Cloning and functional expression of the GLP-1 receptor: Demonstration that exendin-4 is an agonist and exendin-3 (9-39) is an antagonist of the receptor
6. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus
7. Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in Type 2 (non-insulin-dependent) diabetic patients
8. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide- 1 (7-37) in normal and diabetic subjects
9. Gastric emptying, glocose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1-(7-36) amide in Type 2 (non-insulin-dependent) diabetic patients
10. Insulinotropic action of glucagonlike peptide-1-(7-3) in diabetic and non-diabetic subjects
11. The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test
12. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans
13. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
14. Glucose-lowering and insulin-sensitizing actions of exendin-4: Studies on obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
15. Exendin-4 is insulinotropic in non-diabetic and diabetic subjects
16. Adipose tissue volume measured by magnetic resonance imaging and computerized tomography in rats
17. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr)
18. Leptin
19. Exendin-4 potently regulates gastric emptying in rats
20. A role for glucagon-like peptide-1 in the central regulation of feeding
21. Relationship of body fat topography to insulin sensitivity and metabolic profile in premenopausal women
22. Insulin resistance and obesity: The role of fat distribution pattern
23. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat